Verrica Pharmaceuticals Inc.
VRCA
$6.84
$0.6310.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 417.63% | 370.22% | 234.73% | 5.72% | -19.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 417.63% | 370.22% | 234.73% | 5.72% | -19.45% |
| Cost of Revenue | 27.72% | -15.67% | -44.68% | -56.57% | -53.88% |
| Gross Profit | 665.83% | 431.92% | 325.34% | 159.56% | 73.80% |
| SG&A Expenses | -29.16% | -40.12% | -43.92% | -37.55% | -13.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.96% | -35.27% | -44.08% | -42.15% | -25.22% |
| Operating Income | 75.57% | 81.87% | 78.27% | 50.65% | 25.91% |
| Income Before Tax | 72.99% | 76.64% | 69.39% | 44.09% | 18.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.99% | 76.64% | 69.39% | 44.09% | 18.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.99% | 76.64% | 69.39% | 44.09% | 18.27% |
| EBIT | 75.57% | 81.87% | 78.27% | 50.65% | 25.91% |
| EBITDA | 76.06% | 82.34% | 78.76% | 51.04% | 26.35% |
| EPS Basic | 91.39% | 89.54% | 81.16% | 55.79% | 31.22% |
| Normalized Basic EPS | 92.44% | 90.35% | 80.65% | 54.53% | 29.06% |
| EPS Diluted | 91.39% | 89.51% | 81.14% | 55.78% | 31.17% |
| Normalized Diluted EPS | 92.44% | 90.35% | 80.65% | 54.53% | 29.06% |
| Average Basic Shares Outstanding | 112.91% | 105.54% | 89.11% | 63.91% | 38.25% |
| Average Diluted Shares Outstanding | 112.92% | 105.55% | 89.13% | 63.93% | 38.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |